Scientists might have happened upon a new Alzheimer’s pathology. In the July 29 Nature Neuroscience, researchers led by Vilhelm Bohr at the National Institutes of Health, Baltimore, and Paul Robbins ...

Most of the known genetic risk for Alzheimer’s disease is explained by single-letter DNA changes found in genome-wide association studies. Large structural rearrangements, such as copy-number variants ...

Microglia in human brain are descended from progenitor cells that arose in the embryonic yolk sac—but does this remain the case life-long? Two new papers argue that in late adulthood, these original ...

Not all astrocyte lipid droplets are created equal. In the August 19 Nature Communications, scientists led by Priyanka Narayan at the National Institutes of Health in Bethesda, Maryland, report that ...

The FDA has given the nod to two blood tests for Alzheimer’s disease. On August 20 they cleared C2N’s Precivity AD2 test. On August 24, they announced that Roche’s Elecsys p-tau217 passed muster. Both ...

This Notice of Change announces the participation of the National Institute of Neurological Disorders and Stroke (NINDS) in the Notice of Funding Opportunity,"Bioengineering Research Grants (BRG) (R01 ...

How do anti-amyloid antibodies interact with tau pathology? This is still an open question. At last month’s AAIC in London, several scientists addressed how antibodies affect tangles, and how tangles ...

Autosomal-dominant mutations in the progranulin gene halve expression of this critical lysosomal protein, causing an aggressive, early onset form of frontotemporal dementia. Replacement of the lost ...

Bolstered by promising clinical data from brain-shuttled therapies such as trontinemab and tividenofusp, companies are rushing to build brain-shuttle technology into their drug-development pipeline.

With two amyloid immunotherapies in the clinic, it has become urgent to understand the factors that lead to ARIA, and how to avoid this sometimes-serious side effect. At the Alzheimer’s Association ...

Scientists have tried several ways to restrain tau pathology, with varied success. Here’s a new one: alter splicing of the tau gene, MAPT, so that neurons make less of the aggregation-prone 4R isoform ...

Lysosomal dysfunction and neurodegeneration are two processes that often go hand in hand. Now, companion papers in the August 11 Immunity help explain why. Despite focusing on two different ...